

SEQUENCE LISTING

<110> SHEFFIELD, VAL C.
 ALWARD, WALLACE L.M.
 STONE, EDWIN M.
 NISHIMURA, DARRYL
 PATIL, SHIVA

<120> THERAPEUTICS AND DIAGNOSTICS FOR CONGENITAL HEART DISEASE BASED ON A NOVEL HUMAN TRANSCRIPTION FACTOR

<130> IOWA:042USD1

<140> 09/612,809

<141> 2000-07-10

<160> 20

<170> PatentIn Ver. 2.1

<210> 1

<211> 2284

<212> DNA

<213> Homo sapiens

<400> 1

cgagaaaagg tgacgcgggg cccgggcagg cggccggcgc gcggcccccc cccccccgc 60 cctggttatt tggccgcctt cgccggcagc tcagggcaga gtctcctgga aggcgcaggc 120 agtgtggcga gaagggcgcc tgcttgttct ttctttttgt ctgctttccc ccgtttgcgc 180 ctggaagetg egeegegagt teetgeaagg eggtetgeeg eggeegggee eggeettete 240 ccctcgcagc gaccccgcct cgcggccgcg cgggccccga ggtagcccga ggcgccggag 300 gagccagccc cagcgagcgc cgggagaggc ggcagcgcag ccggacgcac agcgcagcgg 360 qccqqcacca gctcggccgg gcccggactc ggactcggcg gccggcgcgg cgcggcccgg 420 cccgagcgag ggtgggggc ggcgggcggc gcgggggggc ggcgagcggg ggcccacacc 480 ctcaaagccg aactaaatcg aaccccaaag caggaaaagc taaaggaacc catcaaggca 540 aaatcgaaac taaaaaaaaa aaatccaatt aaaaaaaacc cctgagaata ttcaccacac 600 cagegaacag aatateette caaaaattea geteaceage accageacga agaaaactet 660 attttcttaa ccgattaatt cagagccacc tccactttgc cttgtctaaa taaacaaacc 720 cgtaaactgt tttatacaga gacagcaaaa tcttggttta ttaaaggaca gtgttactcc 780 agataacacg taagtttctt cttgcttttc agagacctgc tttcccctcc tcccgtctcc 840 cctctcttgc cttcttcctt gcctctcacc tgtaagatat tattttatcc tatgttgaag 900 ggagggggaa agtccccgtt tatgaaagtc gctttctttt tattcatgga cttgttttaa 960 aatgtaaatt gcaacatagt aatttatttt taatttgtag ttggatgtcg tggaccaaac 1020 gccagaaagt gttcccaaaa cctgacgtta aattgcctga aactttaaat tgtgcttttt 1080 ttctcattat aaaaagggaa actgtattaa tcttattcta tcctcttttc tttctttttg 1140 ttgaacatat tcattgtttg tttattaata aattaccatt cagtttgaat gagacctata 1200 tgtctggata ctttaataga gctttaatta ttacgaaaaa agatttcaga gataaaacac 1260 tagaagttac ctattctcca cctaaatctc tgaaaaatgg agaaaccctc tgactagtcc 1320 atgtcaaatt ttactaaaag tetttttgtt tagatttatt tteetgeage atettetgea 1380 aaatgtacta tatagtcagc ttgctttgag gctagtaaaa agatattttt ctaaacagat 1440 tggagttggc atataaacaa atacgttttc tcactaatga cagtccatga ttcggaaatt 1500 ttaagcccat gaatcaqccg cggtcttacc acggtgatgc ctgtgtgccg agagatggga 1560 ctgtgcgcc agatatgcac agataaatat ttggcttgtg tattccatat aaaattgcag 1620 tgcatattat acatecetgt gagecagatg etgaatagat ttttteetat tattteagte 1680 ctttataaaa ggaaaaataa accagttttt aaatgtatgt atataattct cccccattta 1740 caatcettca tqtattacat aqaaqgattg ettttttaaa aatatactge gggttggaaa 1800 qqqatattta atctttqaqa aactatttta gaaaatatgt ttgtagaaca attatttttg 1860 aaaaagattt aaagcaataa caagaaggaa ggcgagagga gcagaacatt ttggtctagg 1920 gtggtttctt tttaaaccat tttttcttgt taatttacag ttaaacctag gggacaatcc 1980 qqattqqccc tccccctttt gtaaataacc caggaaatgt aataaattca ttatcttagg 2040 gtgatctgcc ctgccaatca gactttgggg agatggcgat ttgattacag acgttcgggg 2100 gggtggggg cttgcagttt gttttggaga taatacagtt tcctgctatc tgccgctcct 2160 atctagaggc aacacttaag cagtaattgc tgttgcttgt tgtcaaaatt tgatcattgt 2220 2284 aaaa

<210> 2

<211> 553

<212> PRT

<213> Homo sapiens

<400> 2

Met Gln Ala Arg Tyr Ser Val Ser Ser Pro Asn Ser Leu Gly Val Val 1 5 10 15

Pro Tyr Leu Gly Gly Glu Gln Ser Tyr Tyr Arg Ala Ala Ala Ala Ala 20 25 30

Ala Gly Gly Tyr Thr Ala Met Pro Ala Pro Met Ser Val Tyr Ser 35 40 45

His Pro Ala His Ala Glu Gln Tyr Pro Gly Gly Met Ala Arg Ala Tyr 50 55 60

Gly Pro Tyr Thr Pro Gln Pro Gln Pro Lys Asp Met Val Lys Pro Pro 65 70 75 80

Tyr Ser Tyr Ile Ala Leu Ile Thr Met Ala Ile Gln Asn Ala Pro Asp 85 90 95

Lys Lys Ile Thr Leu Asn Gly Ile Tyr Gln Phe Ile Met Asp Arg Phe 100 105 110

Pro Phe Tyr Arg Asp Asn Lys Gln Gly Trp Gln Asn Ser Ile Arg His
115 120 125

Asn	Leu 130	Ser	Leu	Asn	Glu	Cys 135	Phe	Val	Lys	Val	Pro 140	Arg	Asp	Asp	Lys
Lys 145	Pro	Gly	Lys	Gly	Ser 150	Tyr	Trp	Thr	Leu	Asp 155	Pro	Asp	Ser	Tyr	Asn 160
Met	Phe	Glu	Asn	Gly 165	Ser	Phe	Leu	Arg	Arg 170	Arg	Arg	Arg	Phe	Lys 175	Lys
Lys	Asp	Ala	Val 180	Lys	Asp	Lys	Glu	Glu 185	Lys	Asp	Arg	Leu	His 190	Leu	Lys
Glu	Pro	Pro 195	Pro	Pro	Gly	Arg	Gln 200	Pro	Pro	Pro	Ala	Pro 205	Pro	Glu	Gln
Ala	Asp 210	Gly	Asn	Ala	Pro	Gly 215	Pro	Gln	Pro	Pro	Pro 220	Val	Arg	Ile	Gln
Asp 225	Ile	Lys	Thr	Glu	Asn 230	Gly	Thr	Cys	Pro	Ser 235	Pro	Pro	Gln	Pro	Leu 240
Ser	Pro	Ala	Ala	Ala 245	Leu	Gly	Ser	Gly	Ser 250	Ala	Ala	Ala	Val	Pro 255	Lys
Ile	Glu	Ser	Pro 260	Asp	Ser	Ser	Ser	Ser 265	Ser	Leu	Ser	Ser	Gly 270	Ser	Ser
Pro	Pro	Gly 275	Ser	Leu	Pro	Ser	Ala 280	Arg	Pro	Leu	Ser	Leu 285	Asp	Gly	Ala
Asp	Ser 290	Ala	Pro	Pro	Pro	Pro 295	Ala	Pro	Ser	Ala	Pro 300	Pro	Pro	His	His
Ser 305	Gln	Gly	Phe	Ser	Val 310	Asp	Asn	Ile	Met	Thr 315	Ser	Leu	Arg	Gly	Ser 320
Pro	Gln	Ser	Ala	Ala 325	Ala	Glu	Leu	Ser	Ser 330	Gly	Leu	Leu	Ala	Ser 335	Ala
Ala	Ala	Ser	Ser 340	Arg	Ala	Gly	Ile	Ala 345	Pro	Pro	Leu	Ala	Leu 350	Gly	Ala
Tyr	Ser	Pro 355	Gly	Gln	Ser	Ser	Leu 360	Tyr	Ser	Ser	Pro	Cys 365	Ser	Gln	Thr
Ser	Ser 370	Ala	Gly	Ser	Ser	Gly 375	Gly	Gly	Gly	Gly	Gly 380	Ala	Gly	Ala	Ala

Gly Gly Ala Gly Gly Ala Gly Thr Tyr His Cys Asn Leu Gln Ala Met Ser Leu Tyr Ala Ala Gly Glu Arg Gly Gly His Leu Gln Gly Ala Pro Gly Gly Ala Gly Gly Ser Ala Val Asp Asn Pro Leu Pro Asp Tyr Ser Leu Pro Pro Val Thr Ser Ser Ser Ser Ser Leu Ser His Gly Gly Gly Gly Gly Gly Gly Gly Gly Gln Glu Ala Gly His His Pro Ala Ala His Gln Gly Arq Leu Thr Ser Trp Tyr Leu Asn Gln Ala Gly Gly Asp Leu Gly His Leu Ala Ser Ala Ala Ala Ala Ala Ala Ala Gly Tyr Pro Gly Gln Gln Gln Asn Phe His Ser Val Arg Glu Met Phe Glu Ser Gln Arg Ile Gly Leu Asn Asn Ser Pro Val Asn Gly Asn Ser Ser Cys Gln Met Ala Phe Pro Ser Ser Gln Ser Leu Tyr Arg Thr Ser Gly Ala Phe Val Tyr Asp Cys Ser Lys Phe

<210> 3

<211> 1662

<212> DNA

<213> Homo sapiens

<400> 3

 cqcqacqaca aqaaqccqqq caagggcagc tactggacgc tggacccgga ctcctacaac 480 atgttcgaga acggcagctt cctgcggcgg cggcggcgct tcaagaagaa ggacgcggtg 540 aaqqacaaqq aqqaqaagga caggctgcac ctcaaggagc cgccccgcc cggccgccag 600 cccccgcccg cgccgccgga gcaggccgac ggcaacgcgc ccggtccgca gccgccgccc 660 qtqcqcatcc aqqacatcaa qaccqaqaac qqtacqtqcc cctcqccqcc ccagcccctg 720 tecceggeeg eegeeetggg cageggeage geegeeggg tgeccaagat egagageece 780 qacaqcaqca qcaqcaqcct qtccaqcqqg aqcaqcccc cqqqcaqcct gccqtcgqcq 840 eggeegetea geetggaegg tgeggattee gegeegeege egeeegegee eteegeeeeg 900 ccgccgcacc atagccaggg cttcagcgtg gacaacatca tgacgtcgct gcgggggtcg 960 ccgcagagcg cggccgcgga gctcagctcc ggccttctgg cctcggcggc cgcgtcctcg 1020 cgcgcgggga tcgcaccccc gctggcgctc ggcgcctact cgcccggcca gagctccctc 1080 tacagetece cetgeageca gacetecage gegggeaget egggeggegg eggeggegge 1140 gegggggeeg eggggggege gggeggeectace actgeaacet geaagceatg 1200 agcctgtacg cggccggcga gcgcggggc cacttgcagg gcgcgcccgg gggcgcgggc 1260 ggctcggccg tggacaaccc cctgcccgac tactctctgc ctccggtcac cagcagcagc 1320 tcqtcqtccc tqaqtcacqq cggcqgcggc ggcggcggcg ggggaggcca ggaggccggc 1380 caccaccty cycccacca aggccycetc acctcytygt acctgaacca gycgygcyga 1440 qacctqqqcc acttggcaag cgcggcggcg gcggcggg ccgcaggcta cccgggccag 1500 caqcaqaact tccactcqqt gcgggagatg ttcgagtcac agaggatcgg cttgaacaac 1560 tctccagtga acgggaatag tagctgtcaa atggccttcc cttccagcca gtctctgtac 1620 cqcacqtccq gagctttcgt ctacqactgt agcaagtttt ga 1662

<210> 4

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 4

Pro Lys Asp Met Val Lys Pro Pro Tyr Ser Tyr Ile Ala Leu Ile Thr 1 5 10 15

Met Ala Ile Gln Asn Ala Pro Asp Lys Lys Ile Thr Leu Asn Gly Ile
20 25 30

Tyr Gln Phe Ile Met Asp Arg Phe Pro Phe Tyr Arg Asp Asn Lys Gln 35 40 45

Gly Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Glu Cys Phe
50 55 60

Val Lys Val Pro Arg Asp Asp Lys Lys Pro Gly Lys Gly Ser Tyr Trp 65 70 75 80

Thr Leu Asp Pro Asp Ser Tyr Asn Met Phe Glu Asn Gly Ser Phe Leu 85 90 95

Arg Arg Arg Arg Phe Lys Lys Lys Asp 100 105

<210> 5

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 5

Pro Lys Asp Leu Val Lys Pro Pro Tyr Ser Tyr Ile Ala Leu Ile Thr 1 5 10 15

Met Ala Ile Gln Asn Ala Pro Glu Lys Lys Ile Thr Leu Asn Gly Ile 20 25 30

Tyr Gln Phe Ile Met Asp Arg Phe Pro Phe Tyr Arg Glu Asn Lys Gln 35 40 45

Gly Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Glu Cys Phe 50 55 60

Val Lys Val Pro Arg Asp Asp Lys Lys Pro Gly Lys Gly Ser Tyr Trp 65 70 75 80

Thr Leu Asp Pro Asp Ser Tyr Asn Met Phe Glu Asn Gly Ser Phe Leu 85 90 95

Arg Arg Arg Arg Phe Lys Lys Asp 100 105

<210> 6

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<400	D> Ġ			•											
Thr 1	Thr	Glu	Pro	Thr 5	Lys	Pro	Pro	Tyr	Ser 10	Tyr	Ile	Ala	Leu	Ile 15	Ala
Met	Ala	Ile	Gln 20	Ser	Ser	Pro	Gly	Gln 25	Arg	Ala	Thr	Leu	Ser 30	Gly	Ile
Tyr	Arg	Val 35	Ile	Met	Gly	Arg	Phe 40	Ala	Phe	Tyr	Arg	His	Asn	Arg	Pro
Gly	Trp 50	Gln	Asn	Ser	Ile	Arg 55	His	Asn	Leu	Ser	Leu 60	Asn	Glu	Cys	Phe
Val 65	Lys	Val	Pro	Arg	Asp 70	Asp	Arg	Lys	Pro	Gly 75	Lys	Gly	Ser	Tyr	Trp 80
Thr	Leu	Asp	Pro	Asp 85	Cys	His	Asp	Met	Phe 90	Glu	His	Gly	Ser	Phe 95	Leu
Arg	Arg	Arg	Arg 100	Arg	Phe	Thr	Arg	Gln 105	Thr						
<210> 7 <211> 106 <212> PRT <213> Artificial Sequence															
<220> <223> Description of Artificial Sequence: Synthetic Peptide															
<400)> 7														
Ala 1	Glu	Thr	Pro	Gln 5	Lys	Pro	Pro	Tyr	Ser 10	Tyr	Ile	Ala	Leu	Ile 15	Ala
Met	Ala	Ile	Gln 20	Asp	Ala	Pro	Glu	Gln 25	Arg	Val	Thr	Leu	Asn 30	Gly	Ile
Tyr	Gln	Phe 35	Ile	Met	Asp	Arg	Phe 40	Pro	Phe	Tyr	His	Asp 45	Asn	Arg	Gln

Gly Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Asp Cys Phe

Val Lys Val Pro Arg Glu Lys Gly Arg Pro Gly Lys Gly Ser Tyr Trp

Thr Leu Asp Pro Arg Cys Leu Asp Met Phe Glu Asn Gly Asn Tyr Arg
85 90 95

Arg Arg Lys Arg Lys Pro Lys Pro Gly Pro 100 105

RECEIVED

<210> 8

<211> 106

<212> PRT

<213> Artificial Sequence

OCT 3 1 2002

TECH CENTER 1600/2900

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 8

Pro Leu Gln Arg Gly Lys Pro Pro Tyr Ser Tyr Ile Ala Leu Ile Ala 1 5 10 15

Met Ala Leu Ala His Ala Pro Gly Arg Arg Leu Thr Leu Ala Ala Ile 20 25 30

Tyr Arg Phe Ile Thr Glu Arg Phe Ala Phe Tyr Arg Asp Ser Pro Arg 35 40 45

Lys Trp Gln Asn Ser Ile Arg His Asn Leu Thr Leu Asn Asp Cys Phe 50 55 60

Val Lys Val Pro Arg Glu Pro Gly Asn Pro Gly Lys Gly Asn Tyr Trp 65 70 75 80

Thr Leu Asp Pro Ala Ala Ala Asp Met Phe Asp Asn Gly Ser Phe Leu 85 90 95

Pro Arg Arg Lys Arg Phe Lys Arg Ala Glu 100 105

<210> 9

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<400> 9

Pro Leu Gln Arg Gly Lys Pro Pro Tyr Ser Tyr Ile Ala Leu Ile Ala 1 5 10 15

Met Ala Ile Ala His Ala Pro Glu Arg Arg Leu Thr Leu Gly Gly Ile 20 25 30

Tyr Lys Phe Ile Thr Glu Arg Phe Pro Phe Tyr Arg Asp Asn Pro Lys 35 40 45

Lys Trp Gln Asn Ser Ile Arg His Asn Leu Thr Leu Asn Asp Cys Phe 50 55 60

Leu Lys Ile Pro Arg Glu Ala Gly Arg Pro Gly Lys Gly Asn Tyr Trp 65 70 75 80

Ala Leu Asp Pro Asn Ala Glu Asp Met Phe Glu Ser Gly Ser Phe Leu 85 90 95

Arg Arg Arg Lys Arg Phe Lys Arg Ser Asp 100 105

<210> 10

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 10

Ala Arg Gln Pro Ala Lys Pro Pro Ser Ser Tyr Ile Ala Leu Ile Thr
1 5 10 15

Met Ala Ile Leu Gln Ser Pro His Lys Arg Leu Thr Leu Ser Gly Ile
20 25 30

Cys Ala Phe Ile Ser Asp Arg Phe Pro Tyr Tyr Arg Arg Lys Glu Pro 35 40 45

Gly Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Asp Cys Phe
50 55 60

Val Lys Ile Pro Arg Glu Pro Gly Arg Pro Gly Lys Gly Asn Tyr Trp 65 70 75 80

Ser Leu Asp Pro Ala Ser Gln Asp Met Phe Asp Asn Gly Ser Phe Leu 85 90 95

Arg Arg Arg Lys Arg Phe Gln Arg Asn Gln
100 105

<210> 11

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<400> 11

Arg Thr Arg Leu Val Lys Pro Pro Tyr Ser Tyr Ile Ala Leu Ile Thr 1 5 10 15

Met Ala Ile Leu Gln Ser Pro Lys Lys Arg Leu Thr Leu Ser Glu Ile 20 25 30

Cys Glu Phe Ile Ser Gly Arg Phe Pro Tyr Tyr Arg Glu Lys Phe Pro 35 40 45

Ala Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Asp Cys Phe 50 55 60

Val Lys Ile Pro Arg Glu Pro Gly Asn Pro Gly Lys Gly Asn Tyr Trp 65 70 75 80

Thr Leu Asp Pro Glu Ser Ala Asp Met Phe Asp Asn Gly Ser Phe Leu 85 90 95

Arg Arg Arg Lys Arg Phe Lys Arg Gln Pro 100 105

<210> 12

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<400> 12 Arg Ser Pro Leu Val Lys Pro Pro Tyr Ser Tyr Ile Ala Leu Ile Thr 10 Met Ala Ile Leu Gln Ser Pro Lys Lys Arg Leu Thr Leu Ser Glu Ile 25 Cys Glu Phe Ile Ser Gly Arg Phe Pro Tyr Tyr Arg Glu Lys Phe Pro 35 40 Ala Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Asp Cys Phe 55 Val Lys Ile Pro Arg Glu Pro Gly Asn Pro Gly Lys Gly Asn Tyr Trp 70 75 Thr Leu Asp Pro Glu Ser Ala Asp Met Phe Asp Asn Gly Ser Phe Leu 85 90 Arg Arg Lys Arg Arg Phe Lys Arg Gln Pro 100 105 <210> 13 <211> 106 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic Peptide <400> 13 Ile Arg Arg Pro Glu Lys Pro Pro Tyr Ser Tyr Ile Ala Leu Ile Val 10 Met Ala Ile Gln Ser Ser Pro Thr Lys Arg Leu Thr Leu Ser Glu Ile 25

Gly Trp Lys Asn Ser Val Arg His Asn Leu Ser Leu Asn Glu Cys Phe
50 55 60

Ile Lys Leu Pro Lys Gly Leu Gly Arg Pro Gly Lys Gly His Tyr Trp
65 70 75 80

Tyr Gln Phe Leu Gln Ser Arg Phe Pro Phe Phe Arg Gly Ser Tyr Gln

45

40

35

Thr Ile Asp Pro Ala Ser Glu Phe Met Phe Glu Asn Gly Ser Phe Arg
85 90 95

Arg Arg Arg Gly Phe Arg Arg Lys Cys
100 105

<210> 14

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 14

Leu Arg Arg Pro Glu Lys Pro Pro Tyr Ser Tyr Ile Ala Leu Ile Val 1 5 10 15

Met Ala Ile Gln Ser Ser Pro Ser Lys Arg Leu Thr Leu Ser Glu Ile 20 25 30

Tyr Gln Phe Leu Gln Ala Arg Phe Pro Phe Phe Arg Gly Ala Tyr Gln 35 40 45

Gly Trp Lys Asn Ser Val Arg His Asn Leu Ser Leu Asn Glu Cys Phe 50 55 60

Ile Lys Leu Pro Lys Gly Leu Gly Arg Pro Gly Lys Gly His Tyr Trp 65 70 75 80

Thr Ile Asp Pro Ala Ser Glu Phe Met Phe Glu Asn Gly Ser Phe Arg
85 90 95

Arg Arg Arg Gly Phe Arg Arg Lys Cys
100 105

<210> 15

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<400> 15

Asn Gly Lys Tyr Glu Lys Pro Pro Phe Ser Tyr Asn Ala Leu Ile Met

1 5 10 15

Met Ala Ile Arg Gln Ser Pro Glu Lys Arg Leu Thr Leu Asn Gly Ile 20 25 30

Tyr Glu Phe Ile Met Lys Asn Phe Pro Tyr Tyr Arg Glu Asn Lys Gln 35 40 45

Gly Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Lys Cys Phe 50 55 60

Val Lys Val Pro Arg His Tyr Asp Asp Pro Gly Lys Gly Asn Tyr Trp 65 70 75 80

Met Leu Asp Pro Ser Ser Tyr Asp Asp Val Ile Gly Gly Thr Thr Gly
85 90 95

Lys Leu Arg Arg Arg Ser Thr Thr Ser Pro 100 105

<210> 16

<211> 106

<212> PRT

<213> Artificial Sequence

<400> 16

Asn Gly Lys Tyr Glu Lys Pro Pro Phe Ser Tyr Asn Ala Leu Ile Met

1 5 10 15

Met Ala Met Arg Gln Ser Pro Glu Lys Arg Leu Thr Leu Asn Gly Ile $20 \hspace{1cm} 25 \hspace{1cm} 30$

Tyr Glu Phe Ile Met Lys Asn Phe Pro Tyr Tyr Arg Glu Asn Lys Gln 35 40 45

Gly Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Lys Cys Phe 50 55 60

Val Lys Val Pro Arg His Tyr Asp Asp Pro Gly Lys Gly Asn Tyr Trp 65 70 75 80

Met Leu Asp Pro Ser Ser Tyr Asp Asp Val Ile Gly Gly Thr Thr Gly
85 90 95

Lys Leu Arg Arg Ser Thr Thr Ser Pro Ala

100 105

<210> 17

<211> 106 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic Peptide Gly Lys Tyr Glu Lys Pro Pro Pro Phe Ser Tyr Asn Ala Leu Ile Met 10 Met Ala Ile Arg Gln Ser Pro Glu Lys Arg Leu Thr Leu Asn Gly Ile 20 25 Tyr Glu Phe Ile Met Lys Asn Phe Pro Tyr Tyr Arg Glu Asn Lys Gln 35 40 Gly Trp His Asn Ser Ile Arg Asp Asn Leu Ser Leu Asn Lys Cys Phe 50 55 60 Val Lys Val Pro Arg His Tyr Asp Asp Pro Gly Lys Gly Asn Tyr Trp 65 70 75 80 Met Leu Asp Pro Ser Ser Asp Asp Val Phe Ile Gly Gly Thr Thr Gly 85 Lys Leu Arg Arg Ser Thr Thr Ser Arg 100 105 <210> 18 <211> 76 <212> PRT <213> Artificial Sequence <223> Description of Artificial Sequence: Synthetic Peptide <400> 18 Leu Met Lys Leu Val Arg Pro Pro Tyr Ser Tyr Ser Ala Leu Ile Ala 1 5 10

Met Ala Ile His Gly Ala Pro Asp Lys Arg Leu Thr Leu Ser Gln Ile 25 20 Tyr Gln Tyr Val Ala Asp Asn Phe Pro Phe Tyr Asn Lys Ser Lys Ala 40 35 Gly Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Asp Cys Phe 60 50 55 Lys Lys Val Pro Arg Asp Glu Asp Asp Pro Gly Lys 70 <210> 19 <211> 106 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic Peptide <400> 19 Thr Asn Pro His Val Lys Pro Pro Tyr Ser Tyr Ala Thr Leu Ile Cys 10 5 1 Met Ala Met Gln Ala Ser Lys Ala Thr Lys Ile Thr Leu Ser Ala Ile 20 Tyr Lys Trp Ile Thr Asp Asn Phe Cys Tyr Phe Arg His Ala Asp Pro 40 35 Thr Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Lys Cys Phe 55 Ile Lys Val Pro Arg Glu Lys Asp Glu Pro Gly Lys Gly Gly Phe Trp 75 Arg Ile Asp Pro Gln Tyr Ala Glu Arg Leu Leu Ser Gly Ala Phe Lys 90 85 Lys Arg Arg Leu Pro Phe Val His Ile His 100 105

<210> 20

<211> 98

<212> PRT

<213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic Peptide <400> 20 Trp Gly Asn Leu Ser Tyr Ala Asp Leu Ile Thr Lys Ala Ile Glu Ser Ser Ala Glu Lys Arg Leu Thr Leu Ser Gln Ile Tyr Glu Trp Met Val 25 20 Lys Ser Val Pro Tyr Phe Lys Asp Lys Gly Asp Ser Asn Ser Ser Ala 40 Gly Trp Gln Lys Ser Ile Arg His Asn Leu Ser Leu His Ser Lys Phe 55 Ile Arg Val Gln Asn Glu Gly Thr Gly Lys Ser Ser Trp Trp Met Leu 75 65 70 80

Asn Pro Glu Gly Gly Lys Ser Gly Lys Ser Pro Arg Arg Ala Ala Ser 85 90 95

Met Asp